Modulation and Assessment of Controlled Released Matrix Tablet of Losartan Potassium

Wissenschaftliche Studie aus dem Jahr 2012 im Fachbereich Pharmazie, Institute of Pharmaceutical Education Boradi, Sprache: Deutsch, Abstract: Ideally, a drug should arrive rapidly at the site of action (receptor) in the optimum concentration, remain for the desired time, be excluded from other sites, and be rapidly removed when the goal is achieved. Generally, the time course of a dosage form (pharmacokinetics) in man is considered to be controlled by the chemical structure of the drug. Decreasing the rate of absorption and/or changing the dosage form provide a useful adjunct. When it is not feasible or desirable to modify the drug compound on a molecular level, often sought is a product that will require less frequent administration to obtain the required biological activity time profile. It may be desirable to decrease the absorption rate in order to obtain a more acceptable clinical response. The goal of designing sustained release matrix delivery systems is to reduce frequency of dosing or to increase the effectiveness of the drug by localizing at the site of action, reducing the dose required, or providing uniform drug delivery. Hence, designing a sustained release formulation for an antihypertensive drug may prolong therapeutic concentration of drug in the blood and decrease the frequency of dosing and also improve the patient compliance. So in the present study, attempts will be made to formulate a sustained release matrix tablets containing an antihypertensive drug. In December 1843, a patent was granted to the Englishman, William Brockedon for a machine to compress powders to form compacts. This very simple device consisted essentially a hole (or die) bored through which the powder was compressed between the two cylindrical punches; one was inserted into the base of die and at a fixed depth, the other was inserted at the top of die and struck with hammer. The invention was first used to produce compacts of potassium bicarbonate and caught the imagination of no. of pharmaceutical companies. Later, welcome in Britain was the first company to use the term 'tablet' to describe the compressed dosage form.